



Please type (+) plus sign (+) inside this box

[ ] +

RECEIVED

FEB 06 2002

TECH CENTER 1600/2900

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5

Application Number

09/855,710

Filing Date

May 16, 2002

First Named Inventor

BENNEKER et al.

Group Art Unit

1625

Examiner Name

CHANG, C.

Attorney Docket Number

POT-010US3

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Response to Notice to File Corrected Application Papers and Substitute Specification (31 pages)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm  
or  
Individual name

Mark R. Buscher Reg. No. 35,006

Signature

Date

2/1/02

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: [ ]

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
FEB 06 2002  
TECH CENTER 1600/2900

In re application of:  
BENNEKER, et al.

Application No.: 09/855,710

Filed: May 16, 2001

For: 4-Phenylpiperidine Compounds

Atty. Docket: POT-010US3

Examiner: Chang, C.

Group Art Unit: 1625

**Information Disclosure Statement  
Pursuant To 37 C.F.R. § 1.97(b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

February 1, 2002

Sir:

Applicants hereby direct the attention of the Patent and Trademark Office to the documents listed on the attached Form PTO-1449. Applicants respectfully request that these documents be expressly considered during the prosecution of this application, be made of record therein, and appear among the "References Cited" on any patent to issue therefrom. A copy of each listed document was previously submitted to or cited by the U.S. Patent and Trademark Office in connection with the parent application U.S. Serial Nos. 08/872,023 and 09/200,743. Accordingly, a copy is not required to be submitted herewith. 37 C.F.R. 1.98(d). However, should the Examiner desire to have a copy of one or more of the enclosed listed documents, she is encouraged to contact applicants' undersigned representative and the desired copies will promptly be forwarded to her.

BENNEKER, et al.  
09/855,710

As the Examiner is aware, the submission of this statement is not to be construed as an admission that any document is prior art to the present invention or that any document is material to patentability as defined in rule 56.

This Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(b), before the first Office Action on the merits. Therefore, no fee is due.

Respectfully submitted,

  
Mark R. Buscher  
Mark R. Buscher  
(Reg. No. 35,006)

Synthon Pharmaceuticals, Ltd  
Patent Department  
P.O. Box 161  
Catharpin VA 20143  
703 753 8791